In women aged 35 years or older, does vaping nicotine carry the same contraindication for combined estrogen‑progestin oral contraceptives as smoking cigarettes?

Vaping and Combined Oral Contraceptives: Current Evidence

The current evidence does not support treating vaping the same as cigarette smoking for combined oral contraceptive contraindications, though this reflects a critical gap in research rather than proven safety. 1

The Evidence Gap

• No studies exist examining cardiovascular outcomes in women using combined hormonal contraceptives and electronic cigarettes together. 1
• A 2016 systematic review found zero articles reporting myocardial infarction, stroke, venous thromboembolism, or peripheral arterial disease in women using both e-cigarettes and hormonal contraception. 1
• Among 1,012 people exposed to e-cigarettes in general population studies, only one myocardial infarction was reported, and cardiovascular markers (heart rate, blood pressure) generally remained normal even when statistically significant changes occurred. 1
• Changes in cardiovascular markers were less pronounced with e-cigarette use compared to conventional cigarette use in three studies. 1

Why Cigarette Smoking Is Absolutely Contraindicated

The contraindication for cigarette smoking in women ≥35 years using combined contraceptives is based on robust evidence:

• Any amount of smoking creates an absolute contraindication to combined estrogen-progestin contraceptives (pills, patches, rings) in women ≥35 years. 2, 3
• The relative risk of myocardial infarction rises to approximately 12.5-fold in smokers ≥35 years using combined contraception, especially with >15-20 cigarettes daily. 2, 3, 4
• Smoking and estrogen-containing contraceptives create a synergistic thrombotic risk mediated by increased PAI-1 (plasminogen activator inhibitor-1) and altered hepatic estrogen metabolism. 3, 5
• The majority of coronary and cerebrovascular events among contraceptive users occur in women aged 35-40 years, with smoking as the principal contributor. 2, 3

The Mechanistic Uncertainty with Vaping

• Nicotine alone (without combustion products) has been studied with oral contraceptives in animal models, showing altered brain energy metabolism and exacerbated ischemic stroke injury. 5
• However, one animal study paradoxically showed that combined nicotine and oral contraceptive exposure prevented insulin resistance-linked cardio-renal toxicity, suggesting complex interactions that differ from cigarette smoking. 6
• The key difference is that cigarette combustion products—not just nicotine—drive the thrombotic synergy with estrogen. 3

Clinical Decision Algorithm

For women ≥35 years considering combined hormonal contraception:

1. If smoking cigarettes (any amount):

   • Combined hormonal contraception is absolutely contraindicated. 2, 3
   • Offer progestin-only pills, levonorgestrel IUD, etonogestrel implant, or copper IUD immediately. 2, 3

2. If vaping nicotine:

   • Exercise extreme caution and acknowledge the absence of safety data. 1
   • Given the lack of evidence, the prudent approach is to treat vaping as a relative contraindication and strongly recommend progestin-only or non-hormonal alternatives. 2, 3
   • If the patient insists on combined contraception, document the unknown risks and ensure no other cardiovascular risk factors exist (blood pressure <140/90 mmHg, no migraine with aura, no personal/family history of thromboembolism, no diabetes, no dyslipidemia). 2

3. Safe alternatives for all nicotine users:

   • Progestin-only pills show no increase in stroke or myocardial infarction (relative risk for VTE = 0.90,95% CI 0.57-1.45). 3
   • Levonorgestrel IUD carries no thrombosis risk with >99% efficacy. 2, 3
   • Etonogestrel implant provides >99% efficacy without estrogen-related cardiovascular risks. 2, 3
   • Copper IUD offers >99% efficacy with no hormonal or cardiovascular risk. 2, 3

Critical Pitfalls to Avoid

• Do not assume vaping is safe with combined contraceptives simply because data are lacking; absence of evidence is not evidence of safety. 1
• Do not switch to lower-dose estrogen formulations (e.g., 20 µg ethinyl estradiol) for vapers; all estrogen doses carry contraindications when cardiovascular risk factors exist. 2, 7
• Do not consider transdermal patches or vaginal rings as safer alternatives; they share identical contraindications. 2, 3, 7
• Do not delay transitioning to progestin-only methods if the patient continues vaping and is ≥35 years. 3

The Bottom Line

While current guidelines specifically address cigarette smoking and not vaping, the lack of safety data for vaping with combined contraceptives mandates a cautious approach. 1 The safest recommendation for women ≥35 years who vape is to use progestin-only or non-hormonal contraception, which carry no increased cardiovascular risk regardless of nicotine exposure. 2, 3